| Browse All

KALA BIO, Inc. (KALA)

Healthcare | Biotechnology | Arlington, United States | NasdaqCM
0.20 USD +0.01 (4.082%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 0.20 0.00 (-0.002%) ⇩ (April 17, 2026, 7:53 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:01 p.m. EDT

KALA BIO, Inc. (KALA) has been experiencing a steep decline in its stock price over the past few months, with recent prices hovering around $0.16 to $0.23. The stock has shown a strong negative momentum, with a 50-day average change of -36.07% and a 200-day average change of -94.5%. This indicates a significant bearish trend, which is not favorable for short-term traders looking for momentum or a buy-the-dip opportunity. The recent news highlights include a failed Phase 2b trial, which likely contributed to the stock's decline, and a pivot to a revenue model with an AI platform. However, these developments do not appear to have positively impacted the stock price. The company's financials are also concerning, with negative earnings, a low current ratio, and negative book value. Given the lack of dividends and the bearish trend, KALA is not a suitable investment for short-term traders. For long-term investors, the stock's fundamentals are weak, and the company's future prospects are uncertain. Therefore, it is advisable to avoid KALA for both short-term and long-term investments.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.549711
MSTL0.628229
AutoETS0.637705
AutoARIMA0.652626

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 43%
H-stat 15.44
Ljung-Box p 0.000
Jarque-Bera p 0.268
Excess Kurtosis -1.10
Attribute Value
Sector Healthcare
Market Cap 184,875,872
Forward P/E -0.03
Previous Name Kala Pharmaceuticals, Inc.
Website https://www.kalarx.com

Info Dump

Attribute Value
52 Week Change -0.9395137
Address1 1,167 Massachusetts Avenue
All Time High 1,337.5
All Time Low 0.146
Ask 0.2063
Ask Size 1
Average Daily Volume10 Day 2,531,880
Average Daily Volume3 Month 6,973,591
Average Volume 6,973,591
Average Volume10Days 2,531,880
Bid 0.1951
Bid Size 4
Book Value 0.251
City Arlington
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.1989
Current Ratio 3.805
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 0.2052
Day Low 0.188
Display Name KALA BIO
Earnings Timestamp End 1,754,656,200
Earnings Timestamp Start 1,754,310,600
Ebitda -42,092,000
Ebitda Margins 0.0
Enterprise To Ebitda -4.213
Enterprise Value 177,318,880
Eps Forward -6.67
Eps Trailing Twelve Months -3.31
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 781 642 0399
Fifty Day Average 0.2881
Fifty Day Average Change -0.089200005
Fifty Day Average Change Percent -0.30961472
Fifty Two Week Change Percent -93.95137
Fifty Two Week High 20.6
Fifty Two Week High Change -20.4011
Fifty Two Week High Change Percent -0.99034464
Fifty Two Week Low 0.146
Fifty Two Week Low Change 0.0529
Fifty Two Week Low Change Percent 0.36232877
Fifty Two Week Range 0.146 - 20.6
Financial Currency USD
First Trade Date Milliseconds 1,500,557,400,000
Float Shares 867,550,259
Forward Eps -6.67
Forward P E -0.02982009
Free Cashflow -32,981,124
Full Exchange Name NasdaqCM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.000060000002
Held Percent Institutions 0.0075499997
Implied Shares Outstanding 929,491,578
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,666,310,400
Last Split Factor 1:50
Long Business Summary KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Long Name KALA BIO, Inc.
Market us_market
Market Cap 184,875,872
Market State CLOSED
Max Age 86,400
Message Board Id finmb_83652421
Most Recent Quarter 1,767,139,200
Name Change Date 2,026-04-18
Net Income To Common -26,980,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 184,875,874
Open 0.1889
Operating Cashflow -31,991,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 781 996 5252
Post Market Change -0.0015999973
Post Market Change Percent -0.804423
Post Market Price 0.1973
Post Market Time 1,776,469,992
Prev Name Kala Pharmaceuticals, Inc.
Previous Close 0.1911
Price Hint 4
Price To Book 0.79243034
Profit Margins 0.0
Quick Ratio 3.03
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0078
Regular Market Change Percent 4.08163
Regular Market Day High 0.2052
Regular Market Day Low 0.188
Regular Market Day Range 0.188 - 0.2052
Regular Market Open 0.1889
Regular Market Previous Close 0.1911
Regular Market Price 0.1989
Regular Market Time 1,776,456,001
Regular Market Volume 1,669,298
Return On Assets -0.81589997
Return On Equity -2.7918
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 929,491,578
Shares Percent Shares Out 0.0011999999
Shares Short 1,137,572
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 975,765
Short Name KALA BIO, Inc.
Short Percent Of Float 0.0013
Short Ratio 0.07
Source Interval 15
State MA
Symbol KALA
Total Cash 7,557,000
Total Cash Per Share 0.008
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -3.31
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.57651
Two Hundred Day Average Change -3.37761
Two Hundred Day Average Change Percent -0.94438714
Type Disp Equity
Volume 1,669,298
Website https://www.kalarx.com
Zip 2,476